Literature DB >> 1642552

The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins.

T G Besselaar1, N K Blackburn.   

Abstract

A panel of monoclonal antibodies (MAbs) mapping to different antigenic sites on the RVFV G1 and G2 proteins were used to examine the mechanisms involved in neutralization of the virus. Three types of synergistic neutralization of RVFV were observed on mixing various pairs of MAbs. Firstly, enhanced neutralization occurred for two MAb pairs that showed augmented binding for G2. These comprised a combination of a neutralizing MAb with a non-neutralizing antibody, as well as two antibodies which were non-neutralizing individually. In the second category, synergistic neutralization was observed between combinations of MAbs for which increased binding had not been detected. Lastly, mixtures of G1 and G2-specific MAbs were also capable of enhancing neutralization. Post-adsorption neutralization assays revealed that some MAbs neutralized cell-attached virus efficiently, indicating that they can neutralize by inhibiting the infection process after virus attachment. MAbs mapping to G1 IIe, G2I b and G2I c were unable to neutralize adsorbed virus and thus probably neutralize by preventing virus attachment to cells. Several G1-reactive MAbs displayed low level post-adsorption activity, suggesting they may be capable of inhibiting RVFV infectivity at different stages of the replication cycle.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642552     DOI: 10.1007/bf01309641

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  22 in total

1.  Membrane proteins specified by herpes simplex viruses. III. Role of glycoprotein VP7(B2) in virion infectivity.

Authors:  M Sarmiento; M Haffey; P G Spear
Journal:  J Virol       Date:  1979-03       Impact factor: 5.103

2.  Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins.

Authors:  C S Schmaljohn; M D Parker; W H Ennis; J M Dalrymple; M S Collett; J A Suzich; A L Schmaljohn
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

3.  Formation and biologic role of polyoma virus-antibody complexes. A critical role for complement.

Authors:  M B Oldstone; N R Cooper; D L Larson
Journal:  J Exp Med       Date:  1974-08-01       Impact factor: 14.307

4.  Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness.

Authors:  L W Laughlin; J M Meegan; L J Strausbaugh; D M Morens; R H Watten
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

Review 5.  Mechanisms of neutralization of animal viruses: monoclonal antibodies provide a new perspective.

Authors:  R M Iorio
Journal:  Microb Pathog       Date:  1988-07       Impact factor: 3.738

6.  Enhanced neutralization of La Crosse virus by the binding of specific pairs of monoclonal antibodies to the G1 glycoprotein.

Authors:  L Kingsford
Journal:  Virology       Date:  1984-07-30       Impact factor: 3.616

Review 7.  Mechanisms of neutralization of animal viruses.

Authors:  N J Dimmock
Journal:  J Gen Virol       Date:  1984-06       Impact factor: 3.891

Review 8.  The role of viral glycoproteins in adsorption, penetration, and pathogenicity of viruses.

Authors:  P W Choppin; A Scheid
Journal:  Rev Infect Dis       Date:  1980 Jan-Feb

9.  The spread of Rift Valley fever and approaches to its control.

Authors:  R E Shope; C J Peters; F G Davies
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

10.  Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies.

Authors:  N O Lussenhop; R Goertz; M Wabuke-Bunoti; R Gehrz; B Kari
Journal:  Virology       Date:  1988-06       Impact factor: 3.616

View more
  19 in total

1.  A protective bivalent vaccine against Rift Valley fever and bluetongue.

Authors:  Eva Calvo-Pinilla; Alejandro Marín-López; Sandra Moreno; Gema Lorenzo; Sergio Utrilla-Trigo; Luis Jiménez-Cabello; Julio Benavides; Aitor Nogales; Rafael Blasco; Alejandro Brun; Javier Ortego
Journal:  NPJ Vaccines       Date:  2020-07-30       Impact factor: 7.344

2.  Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope.

Authors:  Yan Wu; Yaohua Zhu; Feng Gao; Yongjun Jiao; Babayemi O Oladejo; Yan Chai; Yuhai Bi; Shan Lu; Mengqiu Dong; Chang Zhang; Guangmei Huang; Gary Wong; Na Li; Yanfang Zhang; Yan Li; Wen-Hai Feng; Yi Shi; Mifang Liang; Rongguang Zhang; Jianxun Qi; George F Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-21       Impact factor: 11.205

3.  Development and characterization of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein generated by DNA immunization.

Authors:  Raquel Martín-Folgar; Gema Lorenzo; Hani Boshra; Javier Iglesias; Francisco Mateos; Belén Borrego; Alejandro Brun
Journal:  MAbs       Date:  2010-05-02       Impact factor: 5.857

4.  A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep.

Authors:  Bonto Faburay; Maxim Lebedev; D Scott McVey; William Wilson; Igor Morozov; Alan Young; Juergen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2014-10       Impact factor: 2.133

5.  In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.

Authors:  Herman F Staats; S Munir Alam; Richard M Scearce; Shaun M Kirwan; Julia Xianzhi Zhang; William M Gwinn; Barton F Haynes
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

6.  Efficient cellular release of Rift Valley fever virus requires genomic RNA.

Authors:  Mary E Piper; Dorothy R Sorenson; Sonja R Gerrard
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

Review 7.  Monoclonal antibody therapies against anthrax.

Authors:  Zhaochun Chen; Mahtab Moayeri; Robert Purcell
Journal:  Toxins (Basel)       Date:  2011-08-15       Impact factor: 4.546

Review 8.  Rift Valley fever: biology and epidemiology.

Authors:  Daniel Wright; Jeroen Kortekaas; Thomas A Bowden; George M Warimwe
Journal:  J Gen Virol       Date:  2019-07-16       Impact factor: 5.141

9.  A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep.

Authors:  Bonto Faburay; William C Wilson; Natasha N Gaudreault; A Sally Davis; Vinay Shivanna; Bhupinder Bawa; Sun Young Sunwoo; Wenjun Ma; Barbara S Drolet; Igor Morozov; D Scott McVey; Juergen A Richt
Journal:  Sci Rep       Date:  2016-06-14       Impact factor: 4.379

10.  Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle.

Authors:  William C Wilson; Bonto Faburay; Jessie D Trujillo; Izabela Ragan; Sun-Young Sunwoo; Igor Morozov; Vinay Shivanna; Aaron Balogh; Kinga Urbaniak; D Scott McVey; Dashzeveg Bold; Natasha N Gaudreault; Erin E Schirtzinger; Wenjun Ma; Juergen A Richt
Journal:  Vaccines (Basel)       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.